Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.41 | 2e-13 |
mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.39 | 3e-12 |
mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.31 | 2e-11 |
mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.31 | 1e-10 |
mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.28 | 2e-10 |
mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.27 | 3e-09 |
mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.27 | 6e-09 |
mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.25 | 2e-08 |
mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.26 | 2e-08 |
mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.25 | 6e-08 |